AU2019393785A1 - Carborane compounds, carborane analogs, and methods of use thereof - Google Patents

Carborane compounds, carborane analogs, and methods of use thereof Download PDF

Info

Publication number
AU2019393785A1
AU2019393785A1 AU2019393785A AU2019393785A AU2019393785A1 AU 2019393785 A1 AU2019393785 A1 AU 2019393785A1 AU 2019393785 A AU2019393785 A AU 2019393785A AU 2019393785 A AU2019393785 A AU 2019393785A AU 2019393785 A1 AU2019393785 A1 AU 2019393785A1
Authority
AU
Australia
Prior art keywords
substituted
unsubstituted
alkyl
compound
alkylaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019393785A
Other languages
English (en)
Other versions
AU2019393785A2 (en
Inventor
Chad BENNETT
Christopher Charles COSS
Jeffrey Patrick
Dasheng Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio State Innovation Foundation
Original Assignee
Ohio State Innovation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State Innovation Foundation filed Critical Ohio State Innovation Foundation
Publication of AU2019393785A1 publication Critical patent/AU2019393785A1/en
Publication of AU2019393785A2 publication Critical patent/AU2019393785A2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019393785A 2018-12-03 2019-12-03 Carborane compounds, carborane analogs, and methods of use thereof Abandoned AU2019393785A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862774688P 2018-12-03 2018-12-03
US62/774,688 2018-12-03
US201962798713P 2019-01-30 2019-01-30
US201962798711P 2019-01-30 2019-01-30
US201962798710P 2019-01-30 2019-01-30
US62/798,711 2019-01-30
US62/798,710 2019-01-30
US62/798,713 2019-01-30
PCT/US2019/064228 WO2020117799A1 (en) 2018-12-03 2019-12-03 Carborane compounds, carborane analogs, and methods of use thereof

Publications (2)

Publication Number Publication Date
AU2019393785A1 true AU2019393785A1 (en) 2021-06-17
AU2019393785A2 AU2019393785A2 (en) 2021-06-24

Family

ID=70974874

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019393785A Abandoned AU2019393785A1 (en) 2018-12-03 2019-12-03 Carborane compounds, carborane analogs, and methods of use thereof

Country Status (7)

Country Link
US (2) US20220040210A1 (https=)
EP (1) EP3890750A4 (https=)
JP (1) JP7644006B2 (https=)
CN (1) CN113347979B (https=)
AU (1) AU2019393785A1 (https=)
CA (1) CA3122029A1 (https=)
WO (1) WO2020117799A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115515580A (zh) * 2020-03-11 2022-12-23 俄亥俄州国家创新基金会 使用碳硼烷和碳硼烷类似物调节t细胞活化的方法
WO2023239764A1 (en) * 2022-06-08 2023-12-14 Ohio State Innovation Foundation Methods and compositions for treating lupus

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000043016A1 (en) * 1999-01-22 2000-07-27 Institute Of Medicinal Molecular Design. Inc. DICARBA-closo-DODECABORANE DERIVATIVES
KR100884489B1 (ko) * 2007-02-21 2009-02-18 원광대학교산학협력단 1,3,5-트리아진-4-일-디카르보-클로소-도데카보란 유도체,이의 제조방법 및 이를 포함하는 약학적 조성물
ES2700141T3 (es) * 2007-08-02 2019-02-14 Gilead Biologics Inc Anticuerpos inhibidores LOXL2 y usos de los mismos
DE102007038930B4 (de) * 2007-08-13 2013-12-05 Universität Leipzig Neue chemische Verbindung und deren Verwendung in der Medizin, insbesondere für die Verwendung in der Tumortherapie
JP2010208996A (ja) * 2009-03-11 2010-09-24 Okayama Univ 置換フェニルプロピオン酸誘導体を含有する医薬組成物
CZ2011676A3 (cs) * 2011-10-24 2013-05-02 Ústav organické chemie a biochemie Akademie ved CR, v.v.i. Inhibitory karbonické anhydrasy, zpusob jejich prípravy
CN108884124A (zh) * 2015-09-17 2018-11-23 俄亥俄州创新基金会 碳硼烷化合物及其使用方法

Also Published As

Publication number Publication date
WO2020117799A1 (en) 2020-06-11
CN113347979B (zh) 2024-08-16
CN113347979A (zh) 2021-09-03
EP3890750A4 (en) 2022-08-10
AU2019393785A2 (en) 2021-06-24
US20250281515A1 (en) 2025-09-11
JP2022510008A (ja) 2022-01-25
JP7644006B2 (ja) 2025-03-11
CA3122029A1 (en) 2020-06-11
US20220040210A1 (en) 2022-02-10
EP3890750A1 (en) 2021-10-13

Similar Documents

Publication Publication Date Title
US11771712B2 (en) Carborane compounds and methods of use thereof
US20250281515A1 (en) Carborane compounds, carborane analogs, and methods of use thereof
EP2776387B1 (en) Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction
US20140288077A1 (en) Substituted 4-phenoxyphenol analogs as modulators of proliferating cell nuclear antigen activity
US20140315956A1 (en) Small molecule inhibitors of il-6 and uses thereof
WO2023141538A1 (en) Compositions comprising lipid compounds and methods of making and use thereof
WO2023086365A1 (en) Compositions comprising amino lipid compounds and methods of making and use thereof
US8871983B2 (en) Lipid compounds for suppression of tumorigenesis
US20250188098A1 (en) Carborane compounds and methods of use thereof
HK40053312A (en) Carborane compounds, carborane analogs, and methods of use thereof
HK40053312B (zh) 碳硼烷化合物、碳硼烷类似物及其使用方法
HK1261921B (en) Carborane compounds and methods of use thereof
HK1261921A1 (en) Carborane compounds and methods of use thereof
US20250289837A1 (en) Mitochondriotropic heteroaryl benzamide potassium channel kv1.3 inhibitors
US20220324849A1 (en) Truncated itraconazole analogues and methods of use thereof

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 30 MAY 2021

MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period